| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RTKN2 |
| Uniprot No | Q8IZC4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-609 aa |
| 活性数据 | MEGPSLRGPA LRLAGLPTQQ DCNIQEKIDL EIRMREGIWK LLSLSTQKDQ VLHAVKNLMV CNARLMAYTS ELQKLEEQIA NQTGRCDVKF ESKERTACKG KIAISDIRIP LMWKDSDHFS NKERSRRYAI FCLFKMGANV FDTDVVNVDK TITDICFENV TIFNEAGPDF QIKVEVYSCC TEESSITNTP KKLAKKLKTS ISKATGKKIS SVLQEEDDEM CLLLSSAVFG VKYNLLAHTT LTLESAEDSF KTHNLSINGN EESSFWLPLY GNMCCRLVAQ PACMAEDAFA GFLNQQQMVE GLISWRRLYC VLRGGKLYCF YSPEEIEAKV EPALVVPINK ETRIRAMDKD AKKRIHNFSV INPVPGQAIT QIFAVDNRED LQKWMEAFWQ HFFDLSQWKH CCEELMKIEI MSPRKPPLFL TKEATSVYHD MSIDSPMKLE SLTDIIQKKI EETNGQFLIG QHEESLPPPW ATLFDGNHQM VIQKKVLYPA SEPLHDEKGK KRQAPLPPSD KLPFSLKSQS NTDQLVKDNW GKTSVSQTSS LDTKLSTLMH HLQKPMAAPR KLLPARRNRL SDGEHTDTKT NFEAKPVPAP RQKSIKDILD PRSWLQAQV |
| 分子量 | 69.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的关于重组人RTKN2蛋白的参考文献示例(仅供参考，实际文献请通过学术数据库查询)：
---
1. **文献名称**：*Rhotekin-2 (RTKN2) promotes T-cell leukemia progression through Wnt/β-catenin signaling*
**作者**：Li, X. et al.
**摘要**：研究利用重组人RTKN2蛋白在T细胞白血病模型中发现其通过激活Wnt/β-catenin通路促进肿瘤细胞增殖，为RTKN2的致癌机制提供了依据。
2. **文献名称**：*Recombinant RTKN2 protein enhances colorectal cancer cell migration via PI3K/Akt activation*
**作者**：Zhang, Y. et al.
**摘要**：通过体外实验表明，重组RTKN2蛋白通过调控PI3K/Akt信号通路增强结直肠癌细胞的迁移能力，提示其作为转移标志物的潜力。
3. **文献名称**：*RTKN2 suppresses apoptosis in breast cancer by interacting with BCL-2 family proteins*
**作者**：Wang, H. et al.
**摘要**：研究发现重组RTKN2蛋白通过直接结合BCL-2家族蛋白抑制乳腺癌细胞凋亡，揭示了其在癌症耐药性中的关键作用。
4. **文献名称**：*Recombinant human RTKN2 as a therapeutic target in hepatocellular carcinoma*
**作者**：Chen, J. et al.
**摘要**：动物实验表明，靶向重组RTKN2蛋白的单克隆抗体可显著抑制肝癌小鼠的肿瘤生长，支持RTKN2作为潜在治疗靶点。
---
**备注**：以上内容为示例性模拟，具体文献需通过PubMed、Google Scholar等平台以关键词“recombinant human RTKN2”或“RTKN2 protein function”检索获取。建议结合研究需求筛选近年高质量期刊论文。
Recombinant human Rhotekin 2 (RTKN2) protein is a genetically engineered form of the endogenous RTKN2. a cytosolic protein predominantly expressed in hematopoietic cells and certain cancer types. RTKN2 contains a Rho-binding domain, enabling interaction with GTP-bound Rho proteins, key regulators of cytoskeletal dynamics, cell adhesion, and motility. This protein plays roles in signaling pathways influencing cell proliferation, apoptosis, and differentiation. Studies link RTKN2 to cancer progression, particularly in malignancies like leukemia, colorectal cancer, and lymphoma, where its overexpression correlates with enhanced cell survival, metastasis, and chemoresistance. It also modulates immune responses by interacting with NF-κB and Wnt/β-catenin pathways.
The recombinant form is produced using bacterial or mammalian expression systems, allowing controlled studies of its biochemical properties and interactions. Purified RTKN2 protein serves as a tool for investigating Rho-mediated signaling mechanisms, screening therapeutic inhibitors, or developing diagnostic assays. Its role in diseases makes it a potential biomarker or target for therapies aimed at disrupting oncogenic signaling networks. Research continues to clarify its precise molecular functions and therapeutic relevance.
×
